Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD.

BACKGROUND AND OBJECTIVES Progression of autosomal dominant polycystic kidney disease (ADPKD) is highly variable. On average, protein-truncating PKD1 mutations are associated with the most severe kidney disease among all mutation classes. Here, we report that patients with protein-truncating PKD1 mutations may also have mild kidney disease, a finding not previously well recognized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS From the extended Toronto Genetic Epidemiologic Study of Polycystic Kidney Disease, 487 patients had PKD1 and PKD2 sequencing and typical ADPKD imaging patterns by magnetic resonance imaging or computed tomography. Mayo Clinic Imaging Classification on the basis of age- and height-adjusted total kidney volume was used to assess their cystic disease severity; classes 1A or 1B were used as a proxy to define mild disease. Multivariable linear regression was performed to test the effects of age, sex, and mutation classes on log-transformed height-adjusted total kidney volume and eGFR. RESULTS Among 174 study patients with typical imaging patterns and protein-truncating PKD1 mutations, 32 (18%) were found to have mild disease on the basis of imaging results (i.e., Mayo Clinic Imaging class 1A-1B), with their mutations spanning the entire gene. By multivariable analyses of age, sex, and mutation class, they displayed mild disease similar to patients with PKD2 mutations and Mayo Clinic Imaging class 1A-1B. Most of these mildly affected patients with protein-truncating PKD1 mutations reported a positive family history of ADPKD in preceding generations and displayed significant intrafamilial disease variability. CONCLUSIONS Despite having the most severe mutation class, 18% of patients with protein-truncating PKD1 mutations had mild disease on the basis of clinical and imaging assessment. PODCAST This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_02_18_CJN11100720_final.mp3.

[1]  T. Weimbs,et al.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. , 2019, Cell metabolism.

[2]  A. Paterson,et al.  Intrafamilial Variability of ADPKD , 2019, Kidney International Reports.

[3]  P. McFarlane,et al.  Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease , 2018, Canadian journal of kidney health and disease.

[4]  M. Patterson,et al.  The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Alexander E. Lopez,et al.  A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.

[6]  D. Landsittel,et al.  Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. , 2017, Kidney international.

[7]  R. Gansevoort,et al.  Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease , 2017, The New England journal of medicine.

[8]  Vicente E. Torres,et al.  Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease , 2017, Kidney international reports.

[9]  S. Lynch,et al.  The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.

[10]  Kaleab Z. Abebe,et al.  Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Marie E. Edwards,et al.  Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. , 2016, American journal of human genetics.

[12]  A. Paterson,et al.  Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[13]  V. Torres,et al.  Food Restriction Ameliorates the Development of Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  R. Salomon,et al.  Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[15]  Wim Van Biesen,et al.  Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Kaleab Z. Abebe,et al.  Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[17]  Eric J. Topol,et al.  Protective alleles and modifier variants in human health and disease , 2015, Nature Reviews Genetics.

[18]  Chad A Shaw,et al.  Somatic mosaicism: implications for disease and transmission genetics. , 2015, Trends in genetics : TIG.

[19]  G. Walz,et al.  Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.

[20]  M. Haider,et al.  Imaging-based diagnosis of autosomal dominant polycystic kidney disease. , 2015, Journal of the American Society of Nephrology : JASN.

[21]  S. Hazen,et al.  The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. , 2015, Annual review of medicine.

[22]  C. Wanner,et al.  Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  V. Torres,et al.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. , 2014, The Journal of clinical investigation.

[24]  G. Pazour,et al.  Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease , 2013, Nature Genetics.

[25]  C. Férec,et al.  Type of PKD1 mutation influences renal outcome in ADPKD. , 2013, Journal of the American Society of Nephrology : JASN.

[26]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[27]  B. Eckloff,et al.  Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. , 2012, Journal of the American Society of Nephrology : JASN.

[28]  Zheng Lan,et al.  A missense mutation in PKD1 attenuates the severity of renal disease. , 2012, Kidney international.

[29]  J. Jonsson,et al.  Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[30]  A. Paterson,et al.  Genetic variation of DKK3 may modify renal disease severity in ADPKD. , 2010, Journal of the American Society of Nephrology : JASN.

[31]  A. Paterson,et al.  Family history of renal disease severity predicts the mutated gene in ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.

[32]  V. Torres,et al.  Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. , 2009, Kidney international.

[33]  K. Bae,et al.  Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. , 2008, Kidney international.

[34]  F. Cosio,et al.  Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[35]  G. Brosnahan,et al.  Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.

[36]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[37]  Ann M. Johnson,et al.  Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[38]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[39]  M. Breuning,et al.  Autosomal dominant polycystic kidney disease: modification of disease progression , 2001, The Lancet.

[40]  A. Paterson,et al.  Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. , 2001, American journal of human genetics.

[41]  E. Coto,et al.  Comparison of phenotypes of polycystic kidney disease types 1 and 2 , 1999, The Lancet.

[42]  Bradley J Erickson,et al.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.

[43]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .